UAB To Test Potential COVID-19 Vaccine
By BirminghamWatch
The University of Alabama at Birmingham and the biopharmaceutical company Altimmune Inc. will test a potential vaccine for COVID-19, the university announced today.
Testing of the vaccine, AdCOVID, which was developed by the company based in Gaithersburg, Maryland, will begin in mice during the second quarter of this year. That phase of testing, designed to show the immune response to the drug in mice, is expected to take one to two months, UAB said in announcing the collaboration.
The vaccine is given in a single dose of intranasal spray, UAB said. If results of the tests in mice warrant, Altimmune could launch a Phase 1 human safety trial during the third quarter of this year.
The announcement by UAB said Altimmune “has significant experience in the development of intranasal vaccine candidates for respiratory pathogens, including a seasonal and pandemic influenza vaccine and a vaccine for inhalation anthrax.”
“We are eager to collaborate with Altimmune on this important project,” said Frances E. Lund, the Charles H. McCauley Professor and Chair for the UAB Department of Microbiology. “The expertise and infrastructure at UAB will be invaluable to the rapid progression of this vaccine into clinical studies.
Lund said six labs at UAB will work on the project.
Vipin K. Garg, president and CEO of Altimmune, cited UAB’s role in research in virology and immunology. He said the company was founded through a technology license from UAB in 1997.
“It is critical that the biotechnology industry and academic institutions work together to prevent the further spread of COVID-19, and UAB is an ideal partner to support us in this effort,”Garg said.
UAB also has extensive experience in conducting clinical studies of vaccines and has participated in studies sponsored by the Vaccine Evaluation and Trial Unit, part of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.
The vaccine being tested “will activate mucosal and cellular immune responses, as well as a strong antibody response in the blood,” the announcement said.
“If the AdCOVID vaccine candidate is as stable as Altimmune’s influenza and anthrax vaccines candidates, that may allow inexpensive and efficient distribution of the millions of doses needed for widespread vaccination of populations,” the statement said.
In Miami, deportations are raising concerns among Cuban-Americans
South Florida's Cuban-American community supports President Trump, but some members are uneasy with his immigration policies. "I'm not for deporting people without criminal records."
Performers and video game companies reach deal that ends nearly year-long strike
Performers who do stunt and voice work for video games went on strike in July after reaching a stalemate in negotiations over how companies can use A.I. in game development.
Trump’s EPA plans to repeal climate pollution limits on fossil fuel power plants
The Trump administration plans to get rid of all limits on climate-warming pollution from the nation's fossil fuel power plants. Fossil fuel interests hailed the proposal, which likely faces legal challenges from environmental groups.
Trump’s DOJ makes its most sweeping demand for election data yet
Voting officials say they've never seen a demand like the one the Justice Department sent to Colorado last month.
Rep. McIver is indicted on federal charges related to tussle at immigration facility
The indictment was announced by interim U.S. Attorney for New Jersey Alina Habba. Rep. McIver says the proceedings against her are "a brazen attempt at political intimidation."
Senators grill Trump’s FAA nominee over past effort to alter pilot certification rule
Republic Airways CEO Bryan Bedford was tapped in March to helm the agency. It's critical time for U.S. air travel, following a deadly January collision and ongoing air traffic control system problems.
